LLY logo

Eli Lilly and Company

LLY
Healthcare|Drug Manufacturers - General|US
$1354.00
-10.73 (-0.79%)
DCF Value
$771.70
Tangible Book / Share
$13.81
Graham Number
$177.24
Cash / Share
$5.48

Analyst Consensus

Buy46 analysts
Strong Buy
0
Buy
34
Hold
9
Sell
3
Strong Sell
0
Consensus Target
$1445.12
Implied Upside
+6.7%
Low Target
$940.00
High Target
$1650.00

Price Target Trend

Last Month
$1528.45
11 targets · +13% vs price
Last Quarter
$1456.69
16 targets · +8% vs price
Last Year
$1323.13
64 targets · -2% vs price
All Time
$939.06
145 targets · -31% vs price

Rating Trend

Dec 25
22 buy · 8 hold · 1 sell
Jan 26
22 buy · 8 hold · 1 sell
Feb 26
24 buy · 7 hold · 1 sell
Mar 26
24 buy · 6 hold · 2 sell
Apr 26
24 buy · 6 hold · 1 sell
May 26
24 buy · 6 hold · 2 sell
Jun 26
24 buy · 5 hold · 2 sell
Jul 26
23 buy · 5 hold · 2 sell
Aug 26
24 buy · 4 hold · 2 sell
Sep 26
25 buy · 4 hold · 2 sell
Oct 26
26 buy · 3 hold · 2 sell
Nov 26
26 buy · 3 hold · 2 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 2, 2026Cantor FitzgeraldCarter Gould$1600.00(+14%)$1409.22StreetInsider
Oct 30, 2026RBC Capital$1600.00(+12%)$1425.34StreetInsider
Oct 30, 2026Argus ResearchJasper Hellweg$1550.00(+13%)$1373.00StreetInsider
Oct 30, 2026UBSMichael Yee$1625.00(+18%)$1373.00StreetInsider
Oct 30, 2026BMO CapitalEvan Seigerman$1650.00(+20%)$1373.00StreetInsider
Oct 30, 2026KeyBanc$1497.00(+9%)$1373.00StreetInsider
Oct 30, 2026Wells FargoMohit Bansal$1500.00(+9%)$1373.00StreetInsider
Oct 30, 2026Truist FinancialSrikripa Devarakonda$1612.00(+17%)$1373.00StreetInsider
Oct 26, 2026BernsteinCourtney Breen$1450.00(+14%)$1273.46TheFly
Oct 21, 2026Leerink Partners$1316.00(+4%)$1265.92TheFly
Oct 20, 2026Goldman Sachs$1413.00(+9%)$1300.46TheFly
Oct 8, 2026Cantor FitzgeraldCarter Gould$1440.00(+21%)$1188.72TheFly
Oct 7, 2026Morgan Stanley$1430.00(+21%)$1184.47TheFly
Sep 18, 2026GuggenheimSeamus Fernandez$1284.00(+11%)$1152.13StreetInsider
Sep 15, 2026Berenberg BankKerry Holford$1400.00(+23%)$1137.75StreetInsider
Sep 10, 2026HSBC$940.00(-16%)$1124.16TheFly
Aug 7, 2026UBS$1376.00(+17%)$1177.33TheFly
Aug 6, 2026Cantor Fitzgerald$1410.00(+19%)$1181.00TheFly
Aug 6, 2026Morgan Stanley$1419.00(+21%)$1169.86TheFly
Aug 6, 2026Wells FargoMohit Bansal$1330.00(+14%)$1169.86StreetInsider

Recent Rating Actions

FirmActionRatingDate
Cantor FitzgeraldmaintainOverweightNov 2, 2026
Morgan StanleymaintainOverweightOct 30, 2026
ScotiabankmaintainSector OutperformOct 30, 2026
CitigroupmaintainBuyOct 30, 2026
JP MorganmaintainOverweightOct 30, 2026
UBSmaintainBuyOct 30, 2026
Truist SecuritiesmaintainBuyOct 30, 2026
RBC CapitalmaintainOutperformOct 30, 2026
Argus ResearchmaintainBuyOct 30, 2026
Wells FargomaintainOverweightOct 30, 2026
Leerink PartnersmaintainOutperformOct 21, 2026
RBC CapitalmaintainOutperformOct 12, 2026
Cantor FitzgeraldmaintainOverweightOct 8, 2026
Morgan StanleymaintainOverweightOct 7, 2026
JP MorganmaintainOverweightSep 28, 2026
TD CowenmaintainBuySep 22, 2026
GuggenheimmaintainBuySep 18, 2026
HSBCmaintainReduceSep 10, 2026
Truist SecuritiesmaintainBuyAug 7, 2026
Wells FargomaintainOverweightAug 6, 2026
Cantor FitzgeraldmaintainOverweightAug 6, 2026
CitigroupmaintainBuyJul 15, 2026
BernsteinmaintainOutperformJul 14, 2026
UBSmaintainBuyJul 13, 2026
GuggenheimmaintainBuyJul 13, 2026

Earnings History

Next report: Feb 3, 2027 · EPS est. $11.20
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Oct 29, 2026$7.48$5.71$24.40B$22.58B
Aug 5, 2026$8.38$6.40$22.97B$20.82B
Apr 30, 2026$8.55$6.97$19.80B$17.82B
Feb 4, 2026$7.54$6.91$19.29B$17.94B
Oct 30, 2025$7.02$5.69$17.60B$16.05B
Aug 7, 2025$6.31$5.60$15.56B$14.70B
May 1, 2025$3.34$3.26$12.73B$12.67B
Feb 6, 2025$5.32$5.03$13.53B—

News

Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence

Some of Eli Lilly's products beyond its core therapeutic area are performing well. It also boasts a deep and diversified pipeline.

Nov 6, 2026fool.com
Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery

On Friday, Eli Lilly And Co. (NYSE:LLY) and Hims & Hers Health Inc. (NYSE:HIMS) announced a collaboration to broaden patient access to obesity medications Zepbound and Foundayo through the digital health platform.

Nov 6, 2026benzinga.com
Top Funds Feast On Shell, Microsoft, Palantir And 24 More Stocks

The best mutual funds place massive bets on Microsoft, Palantir and Apple. But that's just the start.

Nov 6, 2026investors.com
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices availab…

Nov 6, 2026prnewswire.com
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform. The agreement brings together Lilly's obesity med.

Nov 6, 2026businesswire.com
2 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY

As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure with compelling growth potential.

Nov 5, 2026zacks.com
AI and Tech Selloff Heats Up: Buy Big Pharma Stock LLY as a Safe Haven?

The massive AI-driven selloff is leaving investors looking for safe-haven stocks. Now might be a good time to consider buying Eli Lilly (LLY) stock for value and huge growth far outside of AI.

Nov 5, 2026zacks.com
4 Healthcare ETFs to Tap Into Eli Lilly's Post-Q3 Earnings Rally

Eli Lilly's post-Q3 earnings rally highlights its surging drug demand. Discover 4 healthcare ETFs offering LLY exposure.

Nov 5, 2026zacks.com
Prediction: The Weight-Loss Drug Boom Could Be Just the Beginning for Lilly

Eli Lilly just crushed earnings and raised guidance, yet the most compelling part of its story has almost nothing to do with what already happened.

Nov 5, 2026247wallst.com
Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end of the trials Detailed Phase 3b TOGETHER-PsA data showed positive results across disease activity, patient-reported and metabolic outcomes at one year for Taltz and Zepbound vs. Taltz alone in adults with psoriatic arthritis and obesity INDIANAPOLIS, Nov. 5, 2026 /…

Nov 5, 2026prnewswire.com
Eli Lilly and Company $LLY Stock Holdings Lifted by Caldwell Trust Co

Caldwell Trust Co increased its stake in Eli Lilly and Company (NYSE: LLY) by 3.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,203 shares of the company's stock after buying an additional 653 shares during the period. Eli Lilly and

Nov 5, 2026defenseworld.net
Eli Lilly and Company $LLY Stock Bought by Compass Financial Management LLC

Compass Financial Management LLC grew its holdings in Eli Lilly and Company (NYSE: LLY) by 19.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,657 shares of the company's stock after acquiring an additional 427 shares during the quarter. Compass

Nov 5, 2026defenseworld.net
Focused Wealth Management Inc Sells 443 Shares of Eli Lilly and Company $LLY

Focused Wealth Management Inc trimmed its stake in shares of Eli Lilly and Company (NYSE: LLY) by 13.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,835 shares of the company's stock after selling 443 shares during the quarter. Focused Wealth

Nov 5, 2026defenseworld.net
Eli Lilly and Company $LLY Stock: AIA Group Ltd Lowers Stake

AIA Group Ltd trimmed its position in shares of Eli Lilly and Company (NYSE: LLY) by 11.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,479 shares of the company's stock after selling 6,337 shares during the quarter. Eli Lilly and Company

Nov 5, 2026defenseworld.net
Eli Lilly: The True Frontier Of Real-World AI Monetization

Eli Lilly is positioned as the primary beneficiary of AI-driven drug discovery, leveraging its scale and research infrastructure. LLY's integration of AI accelerates new molecule development, enabling rapid expansion of product lines and access to untapped markets. Despite a forward P/E of 40, I rate LLY a Buy for the next 2–3 years, anticipating investor euphoria and substantial earnings growth.

Nov 4, 2026seekingalpha.com
Treasury's Refunding Details Are Up Next as Five Large Companies Report Higher Revenue

/PRNewswire/ -- Market Updates News Commentary - U.S. stock index futures were mixed early Wednesday after a split session on Tuesday. As of 2:22 a.m. ET,

Nov 4, 2026prnewswire.com
Eli Lilly: Higher Volume, Lower Realized Prices

Eli Lilly and Company delivered 39% revenue growth, driven by 53% volume gains despite a 15% decline in realized prices; gross margin rose to 83.9%. Eli Lilly's Strong Buy rating reflects robust growth, high margins, and strong momentum, but earnings were impacted by $4.57/share in acquired R&D charges. Two-thirds of revenue comes from tirzepatide (Mounjaro/Zepbound), heightening concentration risk as patent expiration looms and pricing pressure intensifies.

Nov 4, 2026seekingalpha.com
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Nov 3, 2026zacks.com
LLY Stock Up Almost 10% After a Robust Q3: Time to Buy, Sell or Hold?

Eli Lilly and Company's LLY stock has risen 9.6% since it announced solid third-quarter results on Oct. 29. Lilly's third-quarter earnings and revenues comfortably exceeded estimates.

Nov 3, 2026zacks.com
Eli Lilly Just Delivered Another Monster Quarter. But There's More to This Story Than Weight-Loss Drugs

Eli Lilly's weight-loss drugs get all the headlines, but CEO David Ricks is betting the company's next act looks nothing like its last one. Here is what it would actually take for shares to reach $1,700 in 2027.

Nov 3, 2026247wallst.com